Weekly Recap | QBTS.US -3.68%, most brokers rate it buy
I'm LongbridgeAI, I can summarize articles.QBTS closed the week at $20.39, down 3.68%, while the S&P 500 fell 1.43%, leaving the stock trailing the benchmark by roughly 2.25 percentage points. The week followed a sharp sell-off-and-rebound pattern: the stock opened Monday at $20.78 and hit a week high of $21.355 before sliding through Tuesday to Thursday, when it touched a low of $18.44 and settled at $18.80. Friday then staged a powerful rally, with QBTS bouncing back to $20.39, nearly erasing all mid-week losses.
The Week
QBTS closed the week at $20.39, down 3.68%, while the S&P 500 fell 1.43%, leaving the stock trailing the benchmark by roughly 2.25 percentage points. The week followed a sharp sell-off-and-rebound pattern: the stock opened Monday at $20.78 and hit a week high of $21.355 before sliding through Tuesday to Thursday, when it touched a low of $18.44 and settled at $18.80. Friday then staged a powerful rally, with QBTS bouncing back to $20.39, nearly erasing all mid-week losses. The week’s amplitude reached 14.03%, and average daily volume of 13.5m shares came in about 34% below the median, signalling cooling speculative interest.
Key Events
Quantum computing names broadly tracked the move in Treasury yields this week, and QBTS was no exception. Early in the week, the company appointed Kevan P. Krysler, a finance veteran, to its board and audit committee, a move the market read as a governance upgrade as the firm scales. QBTS also expanded its quantum network optimisation collaboration with NTT DOCOMO, reinforcing its strategy of deploying annealing technology in real-world telecom use cases. The mid-week sell-off was sector-wide: rising yields pressured high-multiple growth stocks, and QBTS slid from above $21 to an intraweek low of $18.44, prompting debate about whether the pullback had run its course. On Friday, BMO analysts highlighted an 86% upside to their target price for QBTS, and that catalyst, combined with a broader sector recovery, pushed the stock up more than 8% in the final session, reclaiming the $20 handle.
Analyst Ratings
As of this week, 17 brokers cover QBTS: 15 rate it buy, 1 overweight, and 1 hold, with no sell or underweight ratings. The consensus rating is a strong buy, and the consensus target price sits at $35.24, about 72.8% above the latest close of $20.39. Individual target prices range from $22 to $43, a wide spread that suggests analysts still disagree on QBTS’s long-term valuation anchor. Within the application software industry’s 198 covered names, QBTS ranks 38th, placing it in the top quintile by analyst attention.
The Week Ahead
A batch of US macro data lands on Tuesday, 25 August: FHFA house prices, the Case-Shiller 20-city index, Richmond Fed manufacturing, consumer confidence, and new home sales. Given how sensitive quantum stocks were to rate expectations this week, these prints could again shift the mood around the sector. QBTS itself has no earnings or corporate events on the near-term calendar, but how peer quantum names trade and whether broker coverage continues to expand will indirectly shape the relative pricing of QBTS.
In Short
QBTS followed a classic macro-pressure, event-driven-recovery script this week. Rising Treasury yields triggered a broad sell-off in the quantum space, but a board refresh, a commercial partnership expansion, and a bullish broker note combined to fuel a sharp Friday bounce, narrowing the week’s loss to 3.68%. The company still carries a negative P/E and a PB of roughly 6.9x, so traditional valuation anchors are scarce. Yet 16 of the 17 covering brokers sit on the buy or overweight side, and the consensus target sits far above the spot price, signalling that professional research leans constructive on QBTS’s long-term application story. Whether the stock can hold above $20 will depend on where macro rate expectations head next and whether analyst conviction continues to provide a floor.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.
